Astera Labs (ALAB) SEC Filings, Aug 15-28, 2025

Astera Labs, Inc. (ALAB) Form 144 summary: Philip Mazzara filed a notice to sell 20,000 common shares via Morgan Stanley Smith Barney LLC, with an aggregate market value of $3,584,000 and an approximate sale date of 08/28/2025. The shares were acquired on 03/14/2022 through previously exercised stock options and were paid for in cash. The filing reports 166,219,140 shares outstanding for the issuer. It also records a prior sale by the same person of 7,237 shares on 08/18/2025 for gross proceeds of $1,328,064.80. The filer certifies they are not aware of any undisclosed material adverse information about the issuer.

Astera Labs, Inc. (ALAB) submitted a Form 144 notice reporting a proposed sale of 22,500 shares of common stock through UBS Financial Services Inc. on the NASDAQ with an aggregate market value of $4,014,398.25. The filing lists the securities to be sold on 08/27/2025.

The filing shows all 22,500 shares were acquired by the seller through RSU vesting on four dates: 11/15/2024 (2,187), 02/15/2025 (3,438), 05/15/2025 (8,437), and 08/15/2025 (8,438), which together equal the 22,500 shares proposed for sale. The filer reports nothing to report for securities sold in the past three months. The form includes the required signature attestation about absence of undisclosed material adverse information.

Mohan Jitendra, listed as Chief Executive Officer and a director of Astera Labs, Inc. (ALAB), reported an insider transaction dated 08/20/2025. The filing shows a bona fide gift of 150,000 shares of common stock (transaction code G) transferred at a price of $0 to a non‑affiliated entity. Following the reported transactions, the Form 4 lists total indirect beneficial ownership of 4,130,002 shares held across multiple trusts and estate planning vehicles and several other indirect holdings noted in the filing. The Form 4 was signed by an attorney‑in‑fact, Philip Mazzara, on 08/21/2025.

Gajendra Sanjay, President and COO and a director of Astera Labs, Inc. (ALAB), reported automatic sales on 08/18/2025 to satisfy tax withholding related to the vesting and settlement of previously granted restricted stock units. The reporting shows two automated sell-to-cover transactions totaling 91,441 shares sold at weighted average prices of $183.8342 and $183.1698. These sales were mandated by an issuer election and are described as non-discretionary. After the transactions the filing lists 2,215,428 and 2,170,877 shares reported as directly owned (per line items), and additional indirect holdings through estate planning trusts totaling 6,915,545 shares across three trusts. The Form 4 was signed by an attorney-in-fact on 08/20/2025.

Astera Labs insider Philip Mazzara, the company's General Counsel and Secretary, reported sales of company common stock on 08/18/2025. The sales were automatic "sell-to-cover" transactions to satisfy tax withholding on vested restricted stock units and were not discretionary trades. The filing shows two grouped sales: 3,710 shares at a weighted average price of $183.8344 and 3,527 shares at a weighted average price of $183.1696, with per-share sale price ranges disclosed in each footnote. The reported post-transaction beneficial ownership balances are 175,100 and 171,573 shares respectively as shown on the form.

Astera Labs (ALAB) director and CEO Mohan Jitendra reported sales of common stock equal to 91,441 shares on 08/18/2025 at weighted-average prices near $183.8 and $183.17 per share. These sales were automatic "sell-to-cover" transactions to satisfy tax withholding on vested restricted stock units and were not discretionary trades by the reporting person. After the transactions the reporting person directly owned 2,170,877 shares. The filing also discloses multiple pools of indirectly owned shares held in various trusts and a living trust, each of which the reporting person disclaims beneficial ownership of except for any pecuniary interest.

Michael Truett Tate, Chief Financial Officer and Director of Astera Labs, Inc. (ALAB), reported routine insider transactions on Form 4. On 08/18/2025 he had automatic "sell-to-cover" sales of restricted stock units to satisfy tax withholding, selling 9,668 shares at a weighted-average price of $183.8343 and 9,193 shares at a weighted-average price of $183.1692. After those sales his direct beneficial ownership totals reported are 268,705 and 259,512 shares respectively. On 08/19/2025 he transferred 55,785 shares to the Tate 1997 Living Trust for no consideration and reported corresponding entries showing 203,727 shares held directly and 457,281 shares indirectly by the trust. The filing notes the transfers were non-discretionary sell-to-cover and the trustee disclaims beneficial ownership except for any pecuniary interest.

Astera Labs insider amendment reports multiple disposals and gifts of common stock by Michael Truett Tate, the companys CFO and trustee of the Tate Trust. The Form 4/A shows sales on 08/07/2025 and 08/08/2025: reported disposals include 43,184, 7,550, 15,141, and 34,125 shares sold at weighted-average prices ranging roughly from $169.05 to $174.04. The filing also records two bona fide gifts of 7,500 and 10,000 shares to non-affiliated recipients. Following the reported transactions the filing shows 501,496 shares beneficially owned indirectly by the Tate Trust. The amendment clarifies that a previously reported acquisition by GlobalStar Donor Advised Fund was an administrative error and that the Reporting Person has no pecuniary interest in that fund.

Astera Labs director Stefan A. Dyckerhoff reported insider transactions on 08/13/2025. The filing shows dispositions of common stock: 11,000 shares and 74,154 shares reported as sold. The form lists the reporting person as a director and indicates multiple indirect holdings held through trusts and a limited partnership.

The schedule reports 353,064 shares2,351 shares to be issued upon vesting of restricted stock units and that the reporting person disclaims beneficial ownership except for pecuniary interest.